Nifty 50
- Max Healthcare₹994.9047.80 (5.05%)
- Tata Motors PV₹264.55-22.85 (-7.95%)
- ITC₹294.309.30 (3.26%)
- Tata Steel₹183.34-3.34 (-1.79%)
- Bharti Airtel₹2,155.6049.60 (2.36%)
- Adani Enterprises₹2,642.10-45.90 (-1.71%)
- Tata Consumer ₹1,099.5020.50 (1.90%)
- Bajaj Finance₹1,099.75-17.25 (-1.54%)
- Apollo Hospitals₹8,669143.00 (1.68%)
- JSW Steel₹1,329.90-18.10 (-1.34%)
- Asian Paints₹2,59242.00 (1.65%)
- Coal India₹398.25-5.25 (-1.30%)
- Nestle₹1,282.6019.40 (1.54%)
- Hindalco Industries₹931.40-12.20 (-1.29%)
- HDFC Life Insurance ₹599.907.65 (1.29%)
- Bajaj Finserv₹1,844.20-20.80 (-1.12%)
- Eternal₹368.254.60 (1.26%)
- Bajaj Auto₹10,753-97.00 (-0.89%)
- SBI Life Insurance ₹1,81020.10 (1.12%)
- InterGlobe Aviation₹5,544.70-42.60 (-0.76%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Algo Strategy
- Markets
Stocks
F&O
Mutual Funds
- More
Biocon Gets US FDA Approval for Pebrilzo Breast Cancer Biosimilar; Shares Rise 0.9%
Authored By HDFC SKY | Published at: Nov 16, 2026 10:27 AM IST
Biocon Limited announced that the US Food and Drug Administration (FDA) has approved PEBRILZO (pertuzumab-qcay), a biosimilar to Roche’s Perjeta, for the treatment of HER2-positive breast cancer. The approval strengthens Biocon’s oncology portfolio, although its US commercial launch is scheduled for the third quarter of calendar year 2028 under an existing patent settlement. The announcement follows Q2 FY27 results showing a 52% decline in consolidated net profit to ₹41 crore. Shares traded around ₹367.20 during Monday’s morning session, approximately 0.9% above the reference price shown in the supplied chart.

Open Free Demat Account
Mumbai, November 16: Biocon Limited shares traded higher on Monday after the company announced US FDA approval for PEBRILZO (pertuzumab-qcay) injection, a biosimilar to Perjeta used in treating HER2-positive breast cancer. The approval marks a significant regulatory milestone for Biocon’s oncology business and expands its portfolio of US-approved biosimilars. Shares advanced towards ₹368 during early trading, with the announcement providing a positive backdrop despite the company’s weaker September-quarter earnings.
Biocon Receives US FDA Approval for Pebrilzo Injection
Biocon announced on November 16, 2026, that the US FDA had approved PEBRILZO (pertuzumab-qcay), its biosimilar version of Perjeta. The medicine is a HER2-targeted therapy used in combination with other treatments for certain patients with HER2-positive breast cancer. The approval covers specified metastatic, early-stage and neoadjuvant breast cancer treatment settings, in line with the product’s prescribing information. Biocon said the approval was supported by a comprehensive development programme involving analytical, nonclinical and clinical studies demonstrating biosimilarity to the reference medicine. According to the company, the clinical evidence showed no clinically meaningful differences between PEBRILZO and Perjeta in terms of quality, safety, efficacy and immunogenicity. Shreehas Tambe, CEO and Managing Director of Biocon, described the approval as an important step towards improving access to high-quality biosimilar medicines for patients with HER2-positive breast cancer. The company also highlighted that PEBRILZO is its fifth oncology biosimilar to receive US regulatory approval, strengthening its position in complex biologic medicines.
Biocon Secures US Launch Timeline for Pebrilzo
Although PEBRILZO has received US FDA approval, commercial availability remains subject to the company’s existing patent settlement and licensing arrangements. In October 2026, Biocon entered into a global settlement and licence agreement with Genentech, resolving patent disputes involving its pertuzumab biosimilar. Under the agreement, Biocon secured licensed launch dates beginning in the first quarter of calendar year 2027 in the European Union and United Kingdom, and the third quarter of calendar year 2028 in the United States. Biocon also announced a 10-year biosimilar pertuzumab partnership in Brazil, valued at approximately $400 million. These developments provide a pathway for expanding the company’s oncology biosimilar business across international markets. The US FDA approval is an important regulatory achievement, but it does not mean that commercial sales of PEBRILZO have already started in the United States.
Biocon Q2 FY27 Net Profit Falls 52% to ₹41 Crore
Biocon had reported its financial results for the quarter ended September 30, 2026, on November 4. Consolidated revenue from operations increased approximately 2% year-on-year to ₹4,389 crore, compared with ₹4,296 crore in Q2 FY26. However, consolidated net profit declined 52% to ₹41 crore from ₹85 crore in the corresponding quarter last year. EBITDA fell approximately 7% to ₹865 crore from ₹928 crore, while the EBITDA margin narrowed to 20% from 22%. The company attributed part of the earnings pressure to delayed shipments worth approximately $20 million that could not be recognised as revenue during the September quarter, although the associated costs had already been recorded. Biopharmaceutical revenue increased 5% year-on-year to ₹3,583 crore, supported by growth in both biosimilars and generics. Biosimilars revenue rose 3% to ₹2,809 crore, while generics revenue increased 10% to ₹774 crore. For the first half of FY27, consolidated revenue from operations grew approximately 6% to ₹8,725 crore, while reported net profit increased to ₹182 crore from ₹116 crore. The results reflected continued growth in Biocon’s core biopharmaceutical business, although weaker quarterly profitability and lower operating margins remained concerns.
Stock Market Snapshot
Biocon share price were trading around ₹367.20 during the morning session on Monday, November 16, 2026. According to the supplied intraday chart, the stock’s reference line was near ₹364.05, indicating an approximate gain of ₹3.15 or 0.87%. The exact exchange-verified previous close is not established from the chart. The stock initially traded around ₹364.30 before gradually moving higher during early trading. Shares crossed ₹366 and subsequently climbed towards ₹367.50 around 9:20 AM IST. After a brief decline towards ₹365.50 around 9:30 AM IST, the stock recovered and approached ₹367.80 during the later part of the morning session. By approximately 9:48 AM IST, the share price was around ₹367.20, remaining above the chart’s reference level. The positive movement coincided with the US FDA approval announcement.

About Biocon
Biocon Limited is a Bengaluru-based global biopharmaceutical company engaged in the development, manufacturing and commercialisation of biosimilars, generic medicines and innovative therapies. The company operates across therapeutic areas including oncology, diabetes, immunology and other chronic diseases. Through its biopharmaceutical operations, Biocon supplies medicines to international markets, including the United States, Europe and emerging economies. Its biosimilars portfolio includes treatments across oncology, diabetes and immunology, supported by manufacturing, research and development capabilities.
Conclusion
Biocon’s US FDA approval for PEBRILZO represents an important milestone in its oncology biosimilars business. The regulatory clearance strengthens the company’s product portfolio and supports its longer-term international expansion plans. However, the US commercial launch remains scheduled for 2028 under the existing patent settlement. Shares traded higher during Monday’s morning session, even as the company’s recent Q2 results showed pressure on profitability. Future performance will depend on successful product commercialisation, improvement in operating margins and growth across key biopharmaceutical markets.
Source:
- https://www.nseindia.in/get-quote/equity/BIOCON/Biocon-Limited
Disclaimer
The information shared here is intended solely for informational and educational purposes and does not constitute investment recommendations. While we practice strict due diligence in curating daily market data, readers must perform independent research before trading. To flag any real-time data discrepancies or content concerns, please write to us at content@hdfcsec.com.
More BIOCON News
Open Free Demat Account
₹363
By signing up I certify terms, conditions & privacy policy

Join Us
Add as preferred source on Google


















